Japan Biosimilars Market to Grow with a CAGR of 10.12% through 2030
Rising Healthcare Costs and Demand for Affordable Therapies and
Technological Advancements in Biomanufacturing are expected to drive the Japan
Biosimilars Market growth in the forecast period, 2026-2030
According to TechSci Research report, “Japan
Biosimilars Market – By Region, Competition Forecast & Opportunities, 2030F”,
the Japan Biosimilars Market stood at USD 502.09 Million in 2024 and is
anticipated to grow with a CAGR of 10.12% in the forecast period through 2030.
Regulatory advancements are pivotal in driving the
growth of the biosimilars market in Japan. The Pharmaceuticals and Medical
Devices Agency (PMDA) has established a proactive regulatory framework that
offers clear guidelines for the development and approval of biosimilars. This
approach not only reduces uncertainty for manufacturers but also accelerates
the entry of new biosimilars into the market, encouraging investment in
research and development.
Also, Japan’s alignment with global regulatory
standards, including those set by the European Medicines Agency (EMA) and the
U.S. Food and Drug Administration (FDA), facilitates smoother international
collaborations and market access. This harmonization fosters a competitive
environment for biosimilars, enhancing their market presence and viability.
Government policies and incentives further support
market growth. Tax breaks and grants for biosimilar development make it
economically feasible for companies to engage in biosimilar projects, thereby
stimulating the market and encouraging innovation.
The expiration of patents for several major biologics
presents significant opportunities for biosimilars. As these patents lapse,
biosimilar manufacturers are positioned to introduce competitive alternatives,
enhancing market competition and expanding treatment options at reduced costs.
This influx of biosimilars not only increases market share but also allows them
to penetrate areas previously dominated by originator biologics, driving
overall market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on " Japan Biosimilars Market”
The Japan Biosimilars Market is segmented into product,
application, distribution channel, regional distribution, and company.
Based on distribution channel, the Hospital
Pharmacies segment has emerged as the predominant market leader, Hospital
pharmacies benefit from centralized procurement systems that streamline the
acquisition of medications, including biosimilars. This centralization allows
for bulk purchasing, which often results in cost savings through negotiated
discounts. As biosimilars are typically positioned as cost-effective
alternatives to expensive biologics, hospital pharmacies are well-positioned to
leverage these savings, making them a primary channel for biosimilar
distribution.
Hospital pharmacies are integral to the healthcare
delivery system within hospitals. They are closely connected with the clinical
departments that prescribe biosimilars, such as oncology, rheumatology, and
internal medicine. This integration ensures that hospital pharmacies are the
primary dispensers of biosimilars for in-patient and outpatient care,
particularly for treatments requiring specialized administration and
monitoring. The ability to manage and dispense biosimilars directly to patients
under the hospital's care contributes to their dominant role in the market. Hospital
pharmacies are responsible for adhering to established treatment protocols and
guidelines, which increasingly include biosimilars. These protocols often
prioritize cost-effective treatments without compromising quality, aligning
with the use of biosimilars as substitutes for reference biologics. By adhering
to these protocols, hospital pharmacies drive the adoption of biosimilars,
ensuring that they are consistently included in treatment regimens and
formularies.
Hospital pharmacies provide specialized support and
training for the use of biosimilars. This includes educating healthcare
professionals about the equivalency of biosimilars to originator biologics,
managing patient transitions from reference biologics to biosimilars, and
ensuring proper administration techniques. This level of support fosters
confidence in the use of biosimilars and enhances their acceptance within
hospital settings. Regulatory and reimbursement policies in Japan also
influence the dominance of hospital pharmacies. The Japanese government often
supports the use of biosimilars through favorable reimbursement policies, which
can be more readily managed and implemented through hospital pharmacies. These
policies encourage the adoption of biosimilars in hospital settings, where the
alignment with reimbursement practices and regulatory guidelines is crucial.
Major companies operating in Japan Biosimilars Market
are:
- Novartis AG
- Pfizer Inc.
- Amgen Inc
- Coherus BioSciences, Inc
- Viatris Inc
- Samsung Bioepis Co., Ltd
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“the Japan biosimilars market is poised for
substantial growth, underpinned by a supportive regulatory environment,
increasing demand for cost-effective therapies, and significant advancements in
biomanufacturing technologies. The proactive stance of the Pharmaceuticals and
Medical Devices Agency (PMDA) and alignment with global regulatory standards
facilitate the market entry and adoption of biosimilars. As patents for key
biologics expire, opportunities for biosimilars expand, further driving market
dynamics. Despite challenges such as market acceptance and pricing pressures,
the market outlook remains positive, with ongoing innovations and supportive
government policies expected to foster continued growth and integration of
biosimilars into the Japanese healthcare system.,” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Japan Biosimilars Market, By Product
(Monoclonal Antibodies, Recombinant Hormones, Immunomodulators,
Anti-inflammatory Agents, Other), By Application (Blood Disorders, Growth
Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, Other), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region, Competition Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Japan
Biosimilars Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Japan Biosimilars Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com